Microcap Ledger Aytu Biopharma, Inc $AYTU
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Denver, CO
- Fiscal year end
- June 30
- Shares outstanding
- 10,866,708 [10-K 2026-09-22]
What the company doesAI summary of filing
Aytu BioPharma is a pharmaceutical company that develops and commercializes prescription medications for central nervous system conditions. The company generates revenue by selling products through third-party wholesalers and pharmacies in the United States. Its primary focus is EXXUA (Gepirone), an FDA-approved extended-release medication for major depressive disorder that the company began selling in fiscal 2026, along with an ADHD portfolio consisting of Adzenys and Cotempla, and a pediatric portfolio including Karbinal. The company reported net revenue of $57.6 million for fiscal 2026, with EXXUA contributing $6.6 million, and has accumulated losses of $347.8 million since inception. [10-K 2026-09-22]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | $57.57M | −$14.25M | $3.28M | $26.31M | [10-K 2026-09-22] |
| FY ended Jun 2025 | $66.38M | −$13.56M | −$1.94M | $30.95M | [10-K 2026-09-22] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 6,149,369 | [10-Q 2024-11-13] |
| 2025-02-01 | 6,169,848 | [10-Q 2025-02-12] |
| 2025-05-01 | 6,170,246 | [10-Q 2025-05-14] |
| 2025-09-15 | 9,911,913 | [10-K 2025-09-23] |
| 2025-11-01 | 10,188,208 | [10-Q 2025-11-13] |
| 2026-01-31 | 10,733,208 | [10-Q 2026-02-03] |
| 2026-04-30 | 10,733,208 | [10-Q 2026-05-13] |
| 2026-09-15 | 10,866,708 | [10-K 2026-09-22] |
- Shelf registration
- S-1 filed 2025-06-02; declared effective 2025-06-05 [S-1 2025-06-02]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-28 | Disbrow Joshua R. | grant | 30,000 | — | [4 2026-07-30] |
| 2026-07-28 | Pyszczymuka Greg | grant | 20,000 | — | [4 2026-07-30] |
| 2026-07-28 | Disbrow Jarrett | grant | 15,000 | — | [4 2026-07-30] |
| 2026-07-28 | Selhorn Ryan J | grant | 25,000 | — | [4 2026-07-30] |
| 2026-07-28 | Liu Vivian H | grant | 10,000 | — | [4 2026-07-30] |
| 2026-07-28 | Jain Abhinav | grant | 10,000 | — | [4 2026-07-30] |
| 2026-07-28 | Dockery Carl | grant | 10,000 | — | [4 2026-07-30] |
| 2026-07-28 | Donofrio John Jr. | grant | 10,000 | — | [4 2026-07-30] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-22 | 10-K | Annual report |
| 2026-09-22 | 8-K | Results of operations |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-25 | 8-K | Material agreement terminated |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-04-02 | 8-K | Material agreement entered; Results of operations; Unregistered sale of equity |
| 2026-02-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-03 | 10-Q | Quarterly report |
| 2026-02-03 | 8-K | Results of operations |
| 2026-01-20 | 8-K | Regulation FD disclosure |
Alerts for $AYTU
Email me when Aytu Biopharma, Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.